Target
sunitinib
12 abstracts
Abstract
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,
Abstract
The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Georgetown-Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Quantifying the risk of hypocalcemia in individuals treated with cabozantinib.Org: Stony Brook University Hospital - Cancer Center,
Abstract
Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, Bristol Myers Squibb, Princeton, NJ, Exelixis, Inc., Alameda, CA, IQVIA, Amsterdam, Netherlands,
Abstract
CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Mayo Clinic, Winship Cancer Institute of Emory University,
Abstract
Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.Org: City of Hope Comprehensive Cancer Center, SWOG Statistics and Data Management Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Yale School of Medicine, Yale University,
Abstract
Preliminary results from a phase II study comparing sunitinib alone or with stereotactic body radiotherapy (SBRT) for newly diagnosed oligometastatic renal cell carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.Org: US Food and Drug Administration, U.S. Food and Drug Administration, FDA/CDER, Food and Drug Administration, Oncology Center of Excellence,
Abstract
Quality-of-life measurement in high-risk patients with uveal melanoma receiving adjuvant sunitinib or valproic acid.Org: Thomas Jefferson University, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Pharmacology & Experimental Therapeutics, Sidney Kimmel Medical College at Thomas Jefferson University, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
A novel prognostic model for oligometastatic renal cell carcinoma: COMPARZ study post-hoc analysis.Org: Fudan University Zhongshan Hospital, Department of Urology Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Novartis Oncology, Novartis China,
Abstract
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barts Cancer Institute, Barts Health NHS Trust and the Royal Free NHS Foundation Trust,
Abstract
Immunotherapy and radiotherapy in metastatic uveal melanoma: Results from a single institute study.Org: Houston Methodist Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Retina Consultants of Texas,